Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

The primary market to be back in action with nine new initial public offerings (IPO) set to open for subscription next week. Apart from new public issues, the market will also witness six new ...

Chandan Healthcare IPO: The initial public offer (IPO) of Chandan Healthcare, which runs diagnostic centres in North India, kicked off for subscription on Monday, February 10 and closed on ...

We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

Multiple combination studies are planned this year. Sionna was formed in 2019 and, prior to its IPO, had already secured about $330 million in venture funding from prominent investors such as RA ...